In a series of tweets, the president addressed an unusual controversy stemming from a speech Thursday that New York Fed President John Williams delivered.Marketsread more
Four members of the House Armed Services Committee, including ranking member Mac Thornberry, R-T.X., said moving forward with the contract was critical to U.S. national...Technologyread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
Walmart is making further organizational changes to further integrate its store and digital operations and leadership, according to a memo obtained by CNBC that was sent by...Retailread more
George Nader helped arrange a January 2017 meeting in the Seychelles between Erik Prince and the head of Russia's sovereign wealth fund, who reported directly to Vladimir...Politicsread more
"I'm not hearing people blame the Fed as much as they're blaming tariffs," says CNBC's Jim Cramer.US Economyread more
Earlier, Williams said in a speech that "it's better to take preventative measures than to wait for disaster to unfold."The Fedread more
Gold has been on fire this year and some investors think it is poised to do something it has only done twice since World War II.Marketsread more
The University of Michigan's preliminary print on its consumer sentiment index ticked up to 98.4, from 98.2 in June. Economists polled by Refinitiv expected the preliminary...Economyread more
The mega-cap tech stocks that have led much of the record-long bull run have started to lose steam, but investors are still giving them the benefit of the doubt.Marketsread more
Houston, we have liftoff. Fifty years ago, man landed on the moon and McDonald's and a handful of other stocks took off into the stratosphere. Two of them have more fuel in...Trading Nationread more
PRINCETON, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Ranya Dajani joined Advaxis as Vice President, Corporate Development from Bristol-Myers Squibb Co. (BMS), where she worked for nearly 20 years in business development and finance.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6a9ae7ff-c6f7-4924-9b14-a5f86ecada45
“Ranya brings deep experience in leading strategic corporate positioning and executing dozens of transactions for one of the leading immuno-oncology companies,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “Her extensive corporate development expertise will prove invaluable as we develop multiple cancer immunotherapies with our proprietary Lm Technology™.”
Ms. Dajani held several finance and business development roles at BMS of increasing responsibility before serving as its executive director for investor relations. In her roles in business development, she was responsible for executing several important strategic collaborations, including key partnerships in immuno-oncology. She holds a master’s degree in business administration with a concentration in finance and a master’s of arts in economics, both from Boston University, and a bachelor’s in economics from the University of Michigan.
“With the unique capabilities of Lm Technology™, a robust pipeline of novel product candidates and track record of being a strong collaborator, Advaxis is well positioned to advance immuno-oncology therapies for a wide range of cancers,” said Ms. Dajani. “I am excited to join the team.”
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer- fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology™ immunotherapy, axalimogene filolisbac (AXAL), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted AXAL orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products in human clinical development: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2-expressing solid tumors.
This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.